Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

COTTONE, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.926
EU - Europa 5.966
AS - Asia 4.829
SA - Sud America 788
Continente sconosciuto - Info sul continente non disponibili 302
AF - Africa 166
OC - Oceania 26
Totale 25.003
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.619
SG - Singapore 1.760
RU - Federazione Russa 1.330
CN - Cina 1.150
IT - Italia 1.042
UA - Ucraina 773
DE - Germania 638
BR - Brasile 551
FI - Finlandia 492
HK - Hong Kong 487
VN - Vietnam 438
GB - Regno Unito 426
PL - Polonia 317
IE - Irlanda 300
FR - Francia 243
JP - Giappone 226
CA - Canada 177
IN - India 140
BD - Bangladesh 122
SE - Svezia 117
KR - Corea 114
MX - Messico 59
CO - Colombia 58
NL - Olanda 54
AR - Argentina 50
TR - Turchia 46
BE - Belgio 43
ES - Italia 43
VE - Venezuela 43
IQ - Iraq 42
MY - Malesia 41
PK - Pakistan 41
CI - Costa d'Avorio 38
EC - Ecuador 35
ZA - Sudafrica 33
ID - Indonesia 30
RO - Romania 30
UZ - Uzbekistan 26
AU - Australia 25
SA - Arabia Saudita 23
MA - Marocco 22
AE - Emirati Arabi Uniti 21
CH - Svizzera 17
EG - Egitto 17
PY - Paraguay 17
CL - Cile 16
CR - Costa Rica 16
JM - Giamaica 16
PH - Filippine 16
AT - Austria 14
EE - Estonia 13
KE - Kenya 13
JO - Giordania 12
RS - Serbia 12
NP - Nepal 10
BG - Bulgaria 9
IL - Israele 9
LT - Lituania 9
GR - Grecia 8
LB - Libano 8
TN - Tunisia 8
TW - Taiwan 8
UY - Uruguay 8
HN - Honduras 7
AL - Albania 6
BO - Bolivia 6
DZ - Algeria 6
GE - Georgia 6
IR - Iran 6
KG - Kirghizistan 6
NG - Nigeria 6
PA - Panama 6
PT - Portogallo 6
SC - Seychelles 6
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
NI - Nicaragua 5
XK - ???statistics.table.value.countryCode.XK??? 5
BH - Bahrain 4
BY - Bielorussia 4
CZ - Repubblica Ceca 4
EU - Europa 4
GT - Guatemala 4
KZ - Kazakistan 4
PE - Perù 4
PS - Palestinian Territory 4
QA - Qatar 4
TH - Thailandia 4
AM - Armenia 3
BA - Bosnia-Erzegovina 3
ET - Etiopia 3
HR - Croazia 3
HU - Ungheria 3
LK - Sri Lanka 3
NO - Norvegia 3
SN - Senegal 3
TT - Trinidad e Tobago 3
BB - Barbados 2
BF - Burkina Faso 2
BW - Botswana 2
Totale 24.681
Salva come PNG Salva come JPEG
Città #
Ashburn 1.437
Singapore 1.218
Fairfield 1.142
San Jose 899
Woodbridge 878
Chandler 657
Houston 637
Wilmington 470
Hong Kong 460
Jacksonville 442
Ann Arbor 438
Seattle 426
Cambridge 387
Dublin 299
Zgierz 274
Council Bluffs 268
Santa Clara 246
Moscow 227
Palermo 220
Tokyo 218
Medford 211
Frankfurt am Main 204
Beijing 190
Los Angeles 166
Nanjing 161
Princeton 139
Ho Chi Minh City 133
Altamura 126
Lauterbourg 120
Hanoi 111
Tulsa 109
Des Moines 104
Boardman 95
Dallas 94
New York 94
Dearborn 91
Lawrence 89
San Diego 75
Hefei 71
Munich 71
Milan 62
Montréal 61
Buffalo 59
Mcallen 58
Chicago 57
Shenyang 52
Helsinki 49
Nanchang 47
Phoenix 44
São Paulo 42
Venice 42
Brussels 41
Kumar 41
London 40
The Dalles 40
Abidjan 38
Ludwigshafen am Rhein 38
Atlanta 37
Omaha 37
Seongnam 37
Tianjin 37
Jiaxing 34
Redwood City 30
Hebei 28
Rome 28
Brasília 27
Changsha 27
Brooklyn 26
Saint Petersburg 26
Amsterdam 25
Montreal 24
Philadelphia 24
Bogotá 23
Jinan 23
Auburn Hills 22
Columbus 22
Da Nang 22
Kuala Lumpur 22
San Francisco 22
Guangzhou 21
Orem 21
San Paolo di Civitate 21
Warsaw 21
Haiphong 20
Johannesburg 20
Verona 20
City of London 19
Rio de Janeiro 19
Tashkent 19
Chennai 18
Nuremberg 18
Washington 18
Charlotte 17
Denver 17
Quito 17
San Mateo 17
Shanghai 17
Las Vegas 16
Manchester 15
Orange 15
Totale 15.497
Salva come PNG Salva come JPEG
Nome #
NUTRITION, MALNUTRITION AND DIETARY INTERVENTIONS IN INFLAMMATORY BOWEL DISEASE 599
Prurigo nodularis of Hyde treated with low-dose thalidomide. 367
Incidence of Crohn's disease and Card 15 mutation in a small township in Sicily 289
Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis 258
A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. 244
Cyclosporine or infliximab as rescue therapy in severe 2 refractory ulcerative colitis: Early and long-term data 3 from a retrospective observational study 243
Budesonide MMX and mesalamine to induce remission in patients with ulcerative colitis 243
An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C 243
Severe acute colitis associated with CMV:a prevalence study 242
Physicians' Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease 242
An Unusual Presentation of Zollinger-Ellison Syndrome 237
Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease 237
Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease study 235
Postoperative maintenance therapy for inflammatory bowel disease 234
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. 232
Clinical and endoscopic presentation of primary gastric lymphoma:a multicenter study 230
EFFICACY AND SAFETY OF ENDOSCOPIC BALLOON DILATION OF SYMPTOMATIC INTESTINAL CROHN'S DISEASE STRICTURES 227
JC Virus, Helicobacter pylori, and Oesophageal Achalasia: Preliminary Results from a Retrospective Case-Control Study 225
Infliximab and ulcerative colitis 223
Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases 223
CA-19 to rule out Pancreatic or Biliary Cancer among patients with cholestasis:an unsuitable ? 221
Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in post-operative Crohn's disease 221
COLORECTAL CANCER IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: PRELIMINARY RESULTS FROM AN ONGOING CASE-CONTROL STUDY 221
Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial. 221
Systematic review: macrophage activation syndrome in inflammatory bowel disease 219
A rare case of ulcerative proctitis associated with type B lymphomatoid papulosis and superimposed human cytomegalovirus infection. 216
Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights 215
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Disease: Real-Life Data from the Sicilian Network for Inflammatory Bowel Disease 215
The frame.shift mutation of the NOD2/Card15 gene is significantly increased in ulcerative colitis: an IG-IBD study 213
Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn's disease strictures. 212
Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. 211
Radiologia e malattia celiaca dell'adulto 210
The role of portal vein thrombosis in the clinical course of inflammatory bowel diseases: report on three cases and review of the literature. 209
Complete clinical remission after high dose immune suppression and autologous hematopoietic stem cell transplantation in severe Crohn's disease refractory to immunosuppressive and immunomodulator therapy 208
CLINICAL COURSE OF SEVERE COLITIS: A COMPARISON BETWEEN CROHN'S DISEASE AND ULCERATIVE COLITIS. 206
Antibiotic treatment of Crohn's disease:results of a multicentre double blind randomized placebo controlled trial with Rifamixin 205
An unusual presentation of T-lymphoma in a Crohn's 4 disease patient treated with combo therapy: We are 5 willing to take a risk of serious adverse events for a 6 doubtful benefit? 205
Calprotectin in the prediction of endoscopic post-surgical recurrence in CD 204
MINIMIZING INFLIXIMAB TOXICITY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE 203
Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study 203
Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients 202
Clinical course of ulcerative colitis 200
Infliximab in the treatment of Crohn's disease :predictors of response in an Italian multicenter open study 199
Crohn's disease:a comparative prospective study of transabdominal ultrasonography,small intestine contrastultrasonography and small bowel enema 198
Cytomegalovirus disappearance after treatment for refractory ulcerative colitis in 2 patients treated with infliximab and 1 patient with leukapheresis 197
Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease 196
THE ROLE OF CARD15 MUTATIONS AND SMOKING IN THE COURSE OF DISEASE IN A MEDITERRANEAN AREA 195
Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study 195
Leucocytapheresis in patients with moderate severe steroid dependant Ulcerative Colitis:clinical response without endoscopic response 193
A real life comparison of the efficacy of adalimumab versus golimumab in moderate-to-severe ulcerative colitis. A multicenter experience from the sicilian network for inflammatory bowel disease (SN-IBD) 192
IL-23R determines susceptibility in Crohn's disease in a Mediterranean area 191
Methodological problems in RCTs on IBD 189
Long term follow-up in an incident cohort of 583 pts with CD 186
Radiofrequency thermal ablation vs percutaneous ethanol injection for small hcc in cirrhosis:metanalysis of randomized controlled trials 186
Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease. 184
COULD JC VIRUS PROVOKE METASTASIS IN COLON CANCER? 182
The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound 182
Cytomegalovirus and Inflammmatory bowel disease:is there a link ? 182
Tofacitinib in active ulcerative colitis 182
Infliximab to treat Crohn's disease: an update 181
Cancer in Infliximab-treated or untreated crohn's disease patients:a 2 years longer follow-up from a multicenter matched pair study 179
Improving patients Qol:how the success of treatment can improve workability 179
NEWLY DIAGNOSED NEOPLASIA IN CROHN DISESE PATIENTS TREATED WITH INFLIXIMAB;A 1 YEAR LONGER FOLLOW UP FROM A MULTICENTER MATCHED PAIR STUDY 179
Oral valganciclovir for coloni c dilatation in ulcerative colitis associated with Human cytomegalovirus infection 179
Infliximab prevents Crohn's disease recurrence after ileal resection. 177
Severe acute colitis associated with citomegalovirus 176
ATG16L1 contribution to Crohn's disease risk in Sicily 176
Burden of Crohn's disease: economics and quality of life aspects in Italy. 176
Unusual perforation after balloon dilation in a Crohn's disease patient:report of a case 175
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. 174
Infliximab in moderate to severe sateroid dipendent or refractory severe ulcerative colitis:short term results of 21 case treated 173
Natural history of cytomegalovirus infection in a cohort of patients diagnosed with moderate severe ulcerative colitis 172
Appropriateness of immunosupprerssive drugs in inflammatory bowel disease assessed by RAND method :Italian group for IBD position statement 172
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. 172
VALIDATION OF A MODIFIED MODEL OF TNBS-INDUCED COLITIS IN RATS. HOW TO INDUCE A CHEMICAL COLITIS IN RATS. 170
Ultrasound in Crohn's disease 169
Over-expression of paneth cell-derived anti-microbial peptides in the gut of patients with ankylosing spondylitis and subclinical intestinal inflammation. 169
randomized clinical trials in perianal disease. 168
Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis? 167
Methodology for high-quality studies on course and prognosis of inflammatory bowel disease. 167
a meta-analysis of the placebo rate of clinical relapse and severe endoscopic recurrence in post-operative maintenance therapy in Crohn's disease 166
Intestinal permeability and Genetic determinants in patients,first degree relatives,and controls in a High incidence area's of Crohn's disease in Southern Italy 166
efficacy and safety of endoscopic ballon dilatation of symptomatic gastrointestinal Crohn's disease strictures 165
The sicilian network for inflammatory bowel disease (SN-IBD): preliminary data on efficacy of biological therapy. 165
The role of NOD2/CARD15 mutation and smoking in the course of Crohn's disease in a Mediterranean area 163
Adalimumab in steroid-dependent Crohn's disease patients: Prognostic factors for clinical benefit 163
Smoking therapy may be an extreme cure in exsmokers with steroid-dependent and resistant ulcerative colitis. 163
Marked impact of IL28B genotype in the natural clearance of hepatitis C virus in patients with haemoglobinopathies. 162
Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. 160
Le malattie infiammatorie dell'intestino 158
Early postoperative recurrence of severe crohn's disease, with colonic involvement and associated human cytomegalovirus infection, treated with oral valganciclovir and adalimumab. 158
NOD2/CARD15 FREQUENCY IN CROHN'DISEASE IN SICILY:AN EPIDEMIOLOGICAL STUDY 157
Investigational agents for Crohn's disease. 157
Psychopharmacology treatment and psychological interventions in irritable bowel syndromel 157
Infliximab in the treatment of steroid resistant dependant and fistulating crohn's disease:an analysis of predictors of response in an italian multicenter open study in 573 pts 156
Natural history of Cytomegalovirus infection diagnosed with moderate-severe ulcerative colitis 155
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use. 149
Infliximab and newly diagnosed neoplasia in CD:a multicenter matched pair study 148
Occul Hepatitis B and infliximab induced HBV reactivation 147
PREVALENCE OF CARD15/NOD2 MUTATIONS IN SICILIAN POPULATION 146
Totale 19.953
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.723
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.723
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.013 0 0 0 51 43 54 85 67 162 199 84 268
2022/20231.900 202 365 35 185 242 260 71 172 245 12 91 20
2023/2024781 46 145 39 53 91 150 75 34 2 54 32 60
2024/20252.017 49 101 101 230 88 77 109 147 148 216 252 499
2025/20268.119 416 228 421 589 736 1.149 1.072 873 567 1.544 288 236
2026/20271.839 345 284 1.093 117 0 0 0 0 0 0 0 0
Totale 25.003